Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeongseok | - |
dc.contributor.author | Yoon, Hyuk | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Jung, Sung-Ae | - |
dc.contributor.author | Choi, Chang Hwan | - |
dc.contributor.author | Kim, Eun Soo | - |
dc.contributor.author | Jung, Yunho | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Kim, Tae Oh | - |
dc.contributor.author | Kang, Sang-Bum | - |
dc.contributor.author | Kim, You Sun | - |
dc.contributor.author | Seo, Geom-Seog | - |
dc.contributor.author | Lee, Chang Kyun | - |
dc.contributor.author | Im, Jong Pil | - |
dc.contributor.author | Park, Soo Jung | - |
dc.contributor.author | Park, Dong Il | - |
dc.contributor.author | Ye, Byong Duk | - |
dc.date.accessioned | 2021-12-30T06:40:16Z | - |
dc.date.available | 2021-12-30T06:40:16Z | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 1078-0998 | - |
dc.identifier.issn | 1536-4844 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/52797 | - |
dc.description.abstract | Background: We investigated the real-life effectiveness and safety of vedolizumab (VDZ) induction therapy among Korean patients with Crohn disease (CD) or ulcerative colitis (UC) for whom anti-tumor necrosis factor therapy previously failed. Methods: Adult patients who started VDZ induction therapy at 16 centers were prospectively enrolled in the Korean VDZ nationwide registry. The coprimary outcomes were clinical remission, defined as a Crohn's Disease Activity Index score <150 points and a partial Mayo score <= 2 points with a combined rectal bleeding and stool frequency subscore <= 1 point at week 14 and endoscopic remission defined as a Mayo endoscopic subscore <= 1 point. We also analyzed predictors of clinical remission. Results: Between August 2017 and November 2019, a total of 158 patients (80 with CD and 78 with UC) received VDZ induction therapy. Clinical remission rates among patients with CD and patients with UC were 44.1% and 44.0%, respectively. Among patients with UC, the endoscopic remission rate was 32.4%. Clinical response and remission rates showed increasing trends during induction therapy. Multivariable analysis revealed that clinical response at week 6 was the only predictor of clinical remission at week 14 for both patients with CD and patients with UC. Among patients who experienced 1 or more adverse events (n = 71; 44.9%), disease exacerbation (n = 28; 17.7%) was the most common adverse event. Conclusions: Among Korean patients with CD or UC for whom anti-tumor necrosis factor therapy failed, VDZ induction therapy was effective and safe. The early clinical response was associated with clinical remission after VDZ induction therapy. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.title | Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1093/ibd/izaa361 | - |
dc.identifier.bibliographicCitation | INFLAMMATORY BOWEL DISEASES, v.27, no.12, pp 1931 - 1941 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000728179200017 | - |
dc.identifier.scopusid | 2-s2.0-85118501621 | - |
dc.citation.endPage | 1941 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1931 | - |
dc.citation.title | INFLAMMATORY BOWEL DISEASES | - |
dc.citation.volume | 27 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | vedolizumab | - |
dc.subject.keywordAuthor | Crohn disease | - |
dc.subject.keywordAuthor | ulcerative colitis | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordPlus | HOSPITAL-BASED COHORT | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | INFLIXIMAB TREATMENT | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | TEMPORAL-CHANGE | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | BIOLOGICS | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.